How does my ApoB compare?
A hundred beads, one for each percentile of untreated US adults. Type your number and watch yours light up.
Higher than 79 of 100 untreated US adults.
Line up 100 of them from lowest to highest and you'd be bead 80. 112 mg/dL is 1.12 g/L.
- 60 about 1 in 10 are below
- 90 the middle
- 120 about the 86th
Normal for the population isn't the same as healthy. The middle of the table, 90, is already the top of the goal for borderline risk.
This table doesn't split by age or sex. ApoB rises about half a point a year in young adults, and the goals stay put.
Higher than 79 of 100 untreated US adults.
What your bead means
- It's your place in a crowd, 100 untreated US adults lined up by ApoB.
- The middle isn't the goal. The middle of the table is 90, which is already the top of the goal at borderline or intermediate risk. Fewer than 1 in 10 are under 60.
- 120 is about the 86th percentile, and the 2026 guideline lists 120 or more as something that raises risk.
- On a cholesterol medicine, the table doesn't describe you, since it's people who weren't taking one.
Your goal comes from your risk, so take your number to Is my ApoB high? next.
The table
NHANES 2005 to 2016: 12,696 untreated US adults aged 18 to 85, from the National Lipid Association's 2024 consensus, in mg/dL. Your place is found by drawing a straight line between rows. The table is all adults together, with no split by age or sex.
| Percentile | ApoB | LDL | Non-HDL |
|---|---|---|---|
| 1 | 410.41 g/L | 45 | 59 |
| 5 | 540.54 g/L | 63 | 79 |
| 10 | 610.61 g/L | 72 | 88 |
| 20 | 700.70 g/L | 85 | 103 |
| 30 | 770.77 g/L | 95 | 114 |
| 40 | 840.84 g/L | 104 | 125 |
| 50 | 900.90 g/L | 112 | 135 |
| 60 | 970.97 g/L | 121 | 145 |
| 70 | 1041.04 g/L | 131 | 156 |
| 80 | 1131.13 g/L | 143 | 170 |
| 90 | 1251.25 g/L | 161 | 191 |
| 95 | 1371.37 g/L | 176 | 208 |
| 99 | 1601.60 g/L | 211 | 247 |
The middle of the table is 90, and 90 is already the top of the goal for borderline or intermediate risk. ApoB climbs about half a point a year in young adults, and the 2026 guideline says that normal rise shouldn't be taken as optimal.
2 sources
- Soffer DE, Marston NA, Maki KC and others, Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association, Journal of Clinical Lipidology, 2024pmc.ncbi.nlm.nih.gov
- Blumenthal RS, Morris PB, Gaudino M and others, 2026 ACC/AHA guideline on the management of dyslipidemia, JACC, 2026doi.org
